BridgeBio is significantly advanced its development of the novel treatment for cardiac amyloidosis, leveraging the investigational drug. Early patient results indicates promising outcomes for patients diagnosed from this serious condition. The effort represents the company’s commitment to addressing significant medical needs in a heart field. At